Indivior PLC Asset Resilience Ratio
Indivior PLC asset resilience ratio. Indivior PLC (INDV) has an Asset Resilience Ratio of 0.07% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Indivior PLC to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Indivior PLC (2022–2024)
Asset resilience ratio of Indivior PLC from 2022 to 2024. This chart shows how Indivior PLC's Asset Resilience Ratio has changed over time. Read INDV total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Indivior PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Indivior PLC asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.00 Million | 0.07% |
| Total Liquid Assets | GBX1.00 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Indivior PLC maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Indivior PLC Industry Peers by Asset Resilience Ratio
Compare Indivior PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Indivior PLC Asset Resilience Ratio by Year (2022–2024)
Indivior PLC asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Indivior PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.08% | GBX1.00 Million ≈ $121.67 |
GBX1.32 Billion ≈ $160.48K |
-4.73pp |
| 2023-12-31 | 4.81% | GBX94.00 Million ≈ $11.44K |
GBX1.95 Billion ≈ $237.75K |
-1.92pp |
| 2022-12-31 | 6.73% | GBX119.00 Million ≈ $14.48K |
GBX1.77 Billion ≈ $215.24K |
-- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more